ANNOUNCEMENT Paris, 13th April 2021
The CytoPrevent board strongly supports the European Parliament vote to include hazardous drugs and reprotoxics in the Carcinogens and Mutagens Directive (CMD) to guaranty a safer working environment for healthcare professionals.
On March 25th, 2021 the European Parliament voted for:
- Requiring legislative action – not just guidance – to be implemented this year
- Asking, the European Commission to include hazardous drugs (hazardous medicinal products or HMPs) in Annex I, and reprotoxics, in the CMD
- To include new guidance to ensure that effective prevention measures are put in place and implemented across Europe
The European Commission should include HMPs to the CMD as supported by the Parliament and the majority of Member States.
The Commission will publish in a near future a report to include hazardous drugs (HMPs), in the current revision of the CMD. This report will take into account the positions of many stakeholders: Member States, experts, professionals, patients, employers and workers in healthcare.
To read the original document, click here.